小眼畸形相关转录因子在黑色素瘤转移中的作用

摘要/Abstract

摘要：小眼畸形相关转录因子（MITF）一直是近几年黑色素瘤细胞研究中的热点。异常表达的MITF与黑色素瘤的发生和转移密切相关，且MITF低表达能促进黑色素瘤细胞的侵袭。研究MITF及与其相关的分子和信号通路的调节关系，将进一步加深对恶性黑色素瘤转移分子机制的理解，为开发新的分子靶向药物提供帮助。

贺艳,帖君,唐郡. 小眼畸形相关转录因子在黑色素瘤转移中的作用[J]. 国际肿瘤学杂志, 2017, 44(4): 281-283.

He Yan, Tie Jun, Tang Jun. Role of microphthalmia-associated transcription factor in melanoma metastasis[J]. Journal of International Oncology, 2017, 44(4): 281-283.

［1］ Cheli Y, Giuliano S, Fenouille N, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells［J］. Oncogene, 2012, 31(19): 2461-2470. DOI: 10.1038/onc.2011.425. ［2］ Widmer DS, Cheng PF, Eichhoff OM, et al. Systematic classification of melanoma cells by phenotype-specific gene expression mapping［J］. Pigment Cell Melanoma Res, 2012, 25(3): 343-353. DOI: 10.1111/j.1755-148X.2012.00986.x. ［3］ Wang C, Zhao L, Su Q, et al. Phosphorylation of MITF by AKT affects its downstream targets and causes TP53-dependent cell senescence［J］. Int J Biochem Cell Biol, 2016, 80: 132-142. DOI: 10.1016/j.biocel.2016.09.029. ［4］ Haq R, Yokoyama S, Hawryluk EB, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition［J］. Proc Natl Acad Sci USA, 2013, 110(11): 4321-4326. DOI: 10.1073/pnas.1205575110. ［5］ Pan L, Ma X, Wen B, et al. Microphthalmia-associated transcription factor/T-box factor-2 axis acts through Cyclin D1 to regulate melanocyte proliferation［J］. Cell Prolif, 2015, 48(6): 631-642. DOI: 10.1111/cpr.12227. ［6］ Margue C, Philippidou D, Reinsbach SE, et al. New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion［J］. PLoS One, 2013, 8(9): e73473. DOI: 10.1371/journal.pone.0073473. ［7］ Golan T, Messer AR, AmitaiLange A, et al. Interactions of melanoma cells with distal keratinocytes trigger metastasis via Notch signaling inhibition of MITF［J］. Mol Cell, 2015, 59(4): 664-676. DOI: 10.1016/j.molcel.2015.06.028. ［8］ Yan D, Dong XD, Chen X, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2［J］. PLoS One, 2012, 7(7): e40967. DOI: 10.1371/journal.pone.0040967. ［9］ Mazar J, DeYoung K, Khaitan D, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness［J］. PLoS One, 2010, 5(11): e13779. DOI: 10.1371/journal.pone.0013779. ［10］ Luo C, Merz PR, Chen Y, et al. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2［J］. Cancer Lett, 2013, 341(2): 240-247. DOI: 10.1016/j.canlet.2013.08.021. ［11］ Goswami S, Tarapore RS, Teslaa JJ, et al. MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor mRNA is inhibited by the coding region determinantbinding protein［J］. J Biol Chem, 2010, 285(27): 20532-20540. DOI: 10.1074/jbc.M110.109298. ［12］ Gallagher SJ, Rambow F, Kumasaka M, et al. Beta-catenin inhibits melanocyte migration but induces melanoma metastasis［J］. Oncogene, 2013, 32(17): 22302238. DOI: 10.1038/onc.2012.229. ［13］ Kaur A, Webster MR, Marchbank K, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance［J］. Nature, 2016, 532(7598): 250-254. DOI: 10.1038/nature17392. ［14］ Seong I, Min HJ, Lee JH, et al. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes［J］. PLoS One, 2012, 7(2): e31477. DOI: 10.1371/journal.pone.0031477. ［15］ Dadras SS, Lin RJ, Razavi G, et al. A novel role for microphthalmia-associated transcription factore-regulated pigment epithelium-derived factor during melanoma progression［J］. Am J Pathol, 2015, 185(1): 252-265. DOI: 10.1016/j.ajpath.2014.09.012. ［16］ Nicholas C, Yang J, Peters SB, et al. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.)［J］. PLoS One, 2013, 8(9): e74710. DOI: 10.1371/journal.pone.0074710. ［17］ Pierrat MJ, Marsaud V, Mauviel A, et al. Expression of microphthalmiaassociated transcription factor (MITF), which is critical for melanoma progression, is inhibited by both transcription factor GLI2 and transforming growth factorβ［J］. J Biol Chem, 2012, 287(22): 17996-18004. DOI: 10.1074/jbc.M112.358341. ［18］ Porcelli L, Guida G, Quatrale AE, et al. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy［J］. J Transl Med, 2015, 13: 26. DOI: 10.1186/s12967-015-0385-4. ［19］ Khoja L, Shenjere P, Hodgson C, et al. Prevalence and heteroge-neity of circulating tumour cells in metastatic cutaneous melanoma［J］. Melanoma Res, 2014, 24(1): 40-46. DOI: 10.1097/CMR.0000000000000025. ［20］ WardwellOzgo J, Dogruluk T, Gifford A, et al. HOXA1 drives me-lanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome［J］. Oncogene, 2014, 33(8): 1017-1026. DOI: 10.1038/onc.2013.30. ［21］ Naffouje S, Naffouje R, Bhagwandin S, et al. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival［J］. Melanoma Res, 2015, 25(6): 496-502. DOI: 10.1097/CMR.0000000000000195. ［22］ Xia J, Wang Y, Li F, et al. Expression of microphthalmia transcription factor, S100 protein, and HMB-45 in malignant melanoma and pigmented nevi［J］. Biomed Rep, 2016, 5(3): 327-331. DOI: 10.3892/br.2016.732. ［23］ Guo R, Franco-Palacios M, Russell M, et al. Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers［J］. Int J Clin Exp Pathol, 2013, 6(8): 1658-1664. ［24］ Stemig M, Astelford K, Emery A, et al. Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF［J］. PLoS One, 2015, 10(4): e0123843. DOI: 10.1371/journal.pone.0123843. ［25］ Qi X, Hong J, Chaves L, et al. Antagonistic regulation by the transcription factors C/EBPα and MITF specifies basophil and mast cell fates［J］. Immunity, 2013, 39(1): 97-110. DOI: 10.1016/j.immuni.2013.06.012. ［26］ Guo J, Zhang JF, Wang WM, et al. MicroRNA-218 inhibits melanogenesis by directly suppressing microphthalmia-associated transcription factor expression［J］. RNA Biol, 2014, 11(6): 732-741.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[3]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[4]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英.免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[5]	吴旻杭, 孙文政, 于庆卓, 郭蓉, 叶辉, 杜莹, 邱晋, 安华章, 曹莉莉.RNF43通过β-catenin抑制黑色素瘤细胞PD-L1表达并促进CD8⁺T细胞介导的抗肿瘤免疫反应[J]. 国际肿瘤学杂志, 2023, 50(7): 407-412.
[6]	杨丽蓉, 王羽丰.预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[7]	李雄安, 颜艳艳.丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[8]	马培晗, 张灵敏, 路宁, 张明鑫.麻醉对肝细胞癌复发转移的影响[J]. 国际肿瘤学杂志, 2023, 50(2): 117-121.
[9]	吕璐, 孙鹏飞, 崔腾璐.子宫内膜癌颈部淋巴结转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(11): 701-704.
[10]	赵建昊, 段衍超.多发性骨髓瘤髓外病变发病机制的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 55-59.
[11]	张露, 周菊英, 马辰莺, 林州.复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[12]	彭琛, 谢印通, 张昕, 谢鹏.宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[13]	张绍鹏, 孔远, 潘国强, 朱丽, 王大广.全身化疗联合腹腔热灌注治疗胃癌1例[J]. 国际肿瘤学杂志, 2022, 49(5): 316-318.
[14]	洪安澜, 曹蒙, 王焱, 方方.长非编码RNA作为竞争性内源RNA在黑色素瘤中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(1): 61-64.
[15]	王斌, 周江云, 刘曦.不同放疗方案治疗晚期食管鳞状细胞癌的临床价值评析[J]. 国际肿瘤学杂志, 2021, 48(8): 484-488.

小眼畸形相关转录因子在黑色素瘤转移中的作用

Role of microphthalmia-associated transcription factor in melanoma metastasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价